ArticleJournal of neural transmission (Vienna, Austria : 1996)2025
Investigation of the voice handicaps in Parkinson's disease and determination of the clinical correlates.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Speech impairment is a common and disabling symptom of Parkinson's disease (PD). We aimed to reveal the motor, nonmotor, and other clinical factors that might be associated with voice disturbances in PD. Remarkably, we aimed to present a possible specific clinical phenotype more prone to display speech disturbances. We included all the patients with PD who visited our movement disorders clinic between March 2023 and March 2024 and whose information regarding the clinical features and scale results was fully available. In addition to detailed demographic data, comprehensive clinical assessments were performed. We included 232 PD patients with a mean age of 64.4 ± 10.5 y (F/M = 145/87). The median disease duration was 4 y. The comparative analyses of the patients with and without voice handicaps (VH) revealed that patients with VH had higher disease duration and LED. They got higher scores in all the clinical scales, including MDS-UPDRS 1, 2, 3, 4, FOGQ, FES-I, HAM-A, and HDRS revealing a more severe disease stage However, multiple linear regression models revealed only the MDS-UPDRS 4 score, HAM-A score, and MDS-UPDRS-3 (on) score [- 10,658 + 2297*MDS-UPDRS-4 + 0949*HAI + 0549*MDS-UPDRS-3 (on)] as predictors of VHI. Our results support increasing speech problems with higher motor stage, and motor complication score. Besides, we also draw attention to anxiety, which is associated with speech problems in the general community, but only in an experimental study of PD pathology.
Indexed as
Identifiers
40128404What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.